DK1141728T3 - Påvisning af nyresygdom og behandling deraf - Google Patents

Påvisning af nyresygdom og behandling deraf

Info

Publication number
DK1141728T3
DK1141728T3 DK99959616T DK99959616T DK1141728T3 DK 1141728 T3 DK1141728 T3 DK 1141728T3 DK 99959616 T DK99959616 T DK 99959616T DK 99959616 T DK99959616 T DK 99959616T DK 1141728 T3 DK1141728 T3 DK 1141728T3
Authority
DK
Denmark
Prior art keywords
disease
detection
treatment
kidney disease
disclosed
Prior art date
Application number
DK99959616T
Other languages
English (en)
Inventor
Wayne D Comper
Original Assignee
Univ Monash
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP7843A external-priority patent/AUPP784398A0/en
Application filed by Univ Monash filed Critical Univ Monash
Application granted granted Critical
Publication of DK1141728T3 publication Critical patent/DK1141728T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
DK99959616T 1998-12-21 1999-12-20 Påvisning af nyresygdom og behandling deraf DK1141728T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP7843A AUPP784398A0 (en) 1998-12-21 1998-12-21 Kidney disease detection and treatment
US09/415,217 US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment
PCT/IB1999/002029 WO2000037944A1 (en) 1998-12-21 1999-12-20 Kidney disease detection and treatment

Publications (1)

Publication Number Publication Date
DK1141728T3 true DK1141728T3 (da) 2008-02-04

Family

ID=25645955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99959616T DK1141728T3 (da) 1998-12-21 1999-12-20 Påvisning af nyresygdom og behandling deraf

Country Status (13)

Country Link
US (3) US20020012906A1 (da)
EP (1) EP1141728B1 (da)
JP (2) JP4160263B2 (da)
CN (1) CN1331801A (da)
AT (1) ATE376187T1 (da)
AU (1) AU1674400A (da)
BR (1) BR9916407A (da)
CA (1) CA2356174A1 (da)
DE (1) DE69937368T2 (da)
DK (1) DK1141728T3 (da)
IL (1) IL143892A0 (da)
MX (1) MXPA01006404A (da)
WO (1) WO2000037944A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037944A1 (en) 1998-12-21 2000-06-29 Monash University Kidney disease detection and treatment
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
US7172873B2 (en) 2001-03-28 2007-02-06 Heska Corporation Methods of detecting early renal disease in animals
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
CA2515576C (en) * 2003-02-13 2013-04-30 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
US7482128B2 (en) 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
WO2006058278A2 (en) * 2004-11-24 2006-06-01 Hill's Pet Nutrition, Inc. Methods for improving liver clearance of xenobiotic substances in an animal
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
AU2005322887B2 (en) * 2004-12-30 2010-03-11 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
RU2376035C2 (ru) * 2005-04-19 2009-12-20 Хилл`С Пет Ньютришн, Инк. Способы и композиции для предотвращения и лечения болезни почек у кошек
AU2006242463A1 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
US9808027B2 (en) * 2005-05-20 2017-11-07 Colgate-Palmolive Company Methods for promoting health or wellness in adult animals
EP1896070A4 (en) 2005-06-29 2009-04-29 Hills Pet Nutrition Inc METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF RENAL DISEASE
AU2006279429B2 (en) 2005-08-17 2010-02-25 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
ATE519116T1 (de) * 2007-03-07 2011-08-15 Mosaiques Diagnostics & Therap Verfahren zur normierung der konzentration von analyten in einer urinprobe
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2535718B1 (en) * 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
CA2701571A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide markers for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
EP2255203A2 (de) * 2008-03-19 2010-12-01 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen
CN102159951B (zh) * 2008-07-18 2014-02-26 波士顿医疗中心有限公司 膜性肾病的诊断
NZ591437A (en) * 2008-08-28 2013-07-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105021826A (zh) * 2008-08-29 2015-11-04 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
US20110214990A1 (en) * 2008-09-17 2011-09-08 Mosaiques Diagnostics And Therapeutics Ag Kidney cell carcinoma
CN104076152B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN106370857A (zh) * 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ592488A (en) 2008-11-10 2012-10-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009316387B2 (en) * 2008-11-22 2015-01-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8481324B2 (en) 2008-12-04 2013-07-09 Technion Research And Development Foundation Ltd. Apparatus and methods for diagnosing renal disorders
PT2391653E (pt) * 2009-01-28 2015-02-13 Ind Tech Res Inst Biomarcadores associados a nefropatia
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010279249B2 (en) * 2009-02-06 2015-08-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2010286559B2 (en) * 2009-08-28 2015-01-22 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
CA2779905A1 (en) * 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) * 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CN105158481A (zh) 2010-02-05 2015-12-16 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9029093B2 (en) 2010-02-26 2015-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269847A1 (en) 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8930222B2 (en) * 2010-08-05 2015-01-06 Abbott Laboratories Method and system for managing patient healthcare
DE102010038014B4 (de) * 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
KR101215759B1 (ko) 2010-11-01 2012-12-26 서울대학교산학협력단 오로소뮤코이드를 포함하는 조성물의 용도
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
WO2013067420A1 (en) * 2011-11-03 2013-05-10 Tumlin James A Acth for treatment of kidney disease
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
US9689826B2 (en) 2012-03-11 2017-06-27 Technion Research And Development Foundation Ltd. Detection of chronic kidney disease and disease progression
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA3158996A1 (en) 2013-01-17 2014-07-24 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2016188761A (ja) * 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10300108B2 (en) 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
US20170205427A1 (en) * 2014-07-23 2017-07-20 University Of British Columbia Biomarkers for anderson-fabry disease
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US11243202B2 (en) 2015-04-09 2022-02-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
EP3665705A1 (en) 2017-08-08 2020-06-17 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107561175A (zh) * 2017-08-10 2018-01-09 武汉大学 一种肾小球硬化大鼠模型的评价方法
RU2697722C1 (ru) * 2018-12-06 2019-08-19 Ирина Сергеевна Шатохина Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
CN110632229A (zh) * 2019-09-24 2019-12-31 华兰生物工程重庆有限公司 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry
CA2080250A1 (en) 1991-05-24 1992-11-25 Hirokazu Suzuki Method of diagnosing renal diseases
JPH0682446A (ja) * 1992-08-31 1994-03-22 Wakamoto Pharmaceut Co Ltd 腎疾患の診断法
DE4336498A1 (de) * 1993-10-26 1995-04-27 Bender & Co Gmbh Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen
US5534431A (en) * 1994-02-28 1996-07-09 The Board Of Regents Of The University Of Nebraska Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
WO2000037944A1 (en) 1998-12-21 2000-06-29 Monash University Kidney disease detection and treatment

Also Published As

Publication number Publication date
EP1141728A4 (en) 2005-01-12
CN1331801A (zh) 2002-01-16
CA2356174A1 (en) 2000-06-29
IL143892A0 (en) 2002-04-21
MXPA01006404A (es) 2003-06-06
JP4388515B2 (ja) 2009-12-24
US20040106155A1 (en) 2004-06-03
JP4160263B2 (ja) 2008-10-01
EP1141728A1 (en) 2001-10-10
JP2002533680A (ja) 2002-10-08
EP1141728B1 (en) 2007-10-17
AU1674400A (en) 2000-07-12
US20020012906A1 (en) 2002-01-31
BR9916407A (pt) 2001-09-25
WO2000037944A1 (en) 2000-06-29
DE69937368T2 (de) 2008-07-17
JP2006038877A (ja) 2006-02-09
US20020022236A1 (en) 2002-02-21
US6589748B2 (en) 2003-07-08
ATE376187T1 (de) 2007-11-15
DE69937368D1 (de) 2007-11-29

Similar Documents

Publication Publication Date Title
DK1141728T3 (da) Påvisning af nyresygdom og behandling deraf
DE69530861D1 (de) Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays
CY1113124T1 (el) Μεθοδοι ανιχνευσης αλληλουχιων νουκλεϊκων οξεων σε ουρα
DK0720746T3 (da) Fremgangsmåde, reagens og sæt til detektering af fækalt okkult blod
DE69729156D1 (de) Verfahren zum Nachweis von Komplex-gebundenem Prostata-spezifischem Antigen (kPSA)
DK1137943T3 (da) Fremgangsmåde til påvisning af cancer og reagenser
ATE232559T1 (de) Verfahren zur signalverstärkung
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
IL142971A0 (en) S100 proteins and autoantibodies as serum markers for cancer
CA2213083A1 (en) Detection of antibody production
ATE208040T1 (de) Immunoassay-reagenzien, testsätze und verfahren
DK0912765T3 (da) Bestemmelse af analyter under anvendelse af to markører
KR970702928A (ko) 크립토콕쿠스증에 대해 위험이 큰 면역약화된 환자의 동정 방법(Method to identify immunocompromised patients at high risk for cryptococcosis)
BR9510669A (pt) Método para determinar ou detectar danos em órgão de doador em seguida ao xenotransplante com base em analitos derivados do órgão do doador
DK0788595T3 (da) Fremgangsmåde til undersögelse af immumkompetance